Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Benitec Biopharma (BNTC)
:BNTC
Holding BNTC?
Track your performance easily
BNTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $13.29
Previous CloseN/A
Volume10.71K
Average Volume (3M)76.92K
Market Cap
$256.77M
Enterprise Value$30.13M
Total Cash (Recent Filing)$7.13M
Total Debt (Recent Filing)$313.62K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Feb 17, 2025EPS Estimate
-0.78Last Dividend Ex-Date
Jun 01, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-5.28
Shares Outstanding23,216,425
10 Day Avg. Volume47,188
30 Day Avg. Volume76,924
Standard Deviation0.26
R-Squared0.03
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$25.20Price Target Upside127.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Benitec Biopharma News
PremiumCompany Announcements
Benitec Biopharma Strengthens Leadership with Key Appointments
PremiumCompany Announcements
Benitec Biopharma Awards Bonuses to Key Executives
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe price target for the stock has been increased to $20 from $13, reflecting early evidence of disease reversal.
Market OpportunityNo treatments have been approved for OPMD, highlighting a significant unmet need and opportunity for BB-301 as the first of its kind.
Product PotentialBB-301 offers meaningful clinical benefit at this low dose, potentially providing a significant improvement in patient-reported outcomes for those with limited treatment options for OPMD.
Bears Say
Clinical TrialsDelays in converting patients from the natural history run-in study to the Phase 1/2 trial could push out initial timelines.
Price TargetA placebo-controlled pivotal trial and/or signs of benefit eroding over time could imply an $11 downside to the price target.
Research And DevelopmentR&D spending of $3.5mm was above consensus expectations of $2.6mm, indicating higher costs than anticipated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTC FAQ
What was Benitec Biopharma’s price range in the past 12 months?
Benitec Biopharma lowest stock price was $2.70 and its highest was $13.29 in the past 12 months.
What is Benitec Biopharma’s market cap?
Benitec Biopharma’s market cap is $256.77M.
When is Benitec Biopharma’s upcoming earnings report date?
Benitec Biopharma’s upcoming earnings report date is Feb 17, 2025 which is in 30 days.
How were Benitec Biopharma’s earnings last quarter?
Benitec Biopharma released its earnings results on Nov 14, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.55 by $0.07.
Is Benitec Biopharma overvalued?
According to Wall Street analysts Benitec Biopharma’s price is currently Undervalued.
Does Benitec Biopharma pay dividends?
Benitec Biopharma pays a Notavailable dividend of $0.51 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma dividends here
What is Benitec Biopharma’s EPS estimate?
Benitec Biopharma’s EPS estimate is -0.78.
How many shares outstanding does Benitec Biopharma have?
Benitec Biopharma has 23,216,425 shares outstanding.
What happened to Benitec Biopharma’s price movement after its last earnings report?
Benitec Biopharma reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.55. Following the earnings report the stock price went up 2.692%.
Which hedge fund is a major shareholder of Benitec Biopharma?
Currently, no hedge funds are holding shares in BNTC
---
Benitec Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.20 (127.85% Upside)
$25.20 (127.85% Upside)
Blogger Sentiment
Bullish
BNTC Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.47%
12-Months-Change
Fundamentals
Return on Equity
-48.23%
Trailing 12-Months
Asset Growth
154.22%
Trailing 12-Months
Company Description
Benitec Biopharma
Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in North Sydney, Australia.
---
BNTC Stock 12 Month Forecast
Average Price Target
$25.20
▲(127.85% Upside)
Technical Analysis
Anixa Biosciences
―
Arrowhead Pharmaceuticals
―
Editas Medicine
―
Sorrento Therapeutics
―
Sangamo Biosciences
―
Voyager Therapeutics
―
Best Analysts Covering BNTC
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+11.60%
assigned a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +11.60% per trade.
---